News

Ageas Enhances Shareholder Value with Buy-Back Program Update

Ageas Enhances Shareholder Value with Buy-Back Program Update

Ageas Share Buy-Back Program Progress Report

Regulated Information

Ageas has shared important updates on its ongoing share buy-back program. This strategic initiative was initiated earlier this year, reflecting the company's commitment to enhancing shareholder value.

Recent Share Repurchases

Through the share buy-back program, Ageas has successfully purchased a total of 105,596 shares between October 21 and October 25. These recent transactions are important indicators of the company’s strong financial health and strategic vision.

Detailed Purchase Data

Here’s a concise overview of the shares purchased during this specific period:

Share Transactions Overview

The table below summarises the buybacks made:

Date: 21-10-2024, Number of Shares: 21,186, Total Amount (EUR): 1,038,015, Average Price (EUR): 49.00, Lowest Price (EUR): 48.74, Highest Price (EUR): 49.26.

Date: 22-10-2024, Number of Shares: 21,188, Total Amount (EUR): 1,028,865, Average Price (EUR): 48.56, Lowest Price (EUR): 48.28, Highest Price (EUR): 48.86.

Date: 23-10-2024, Number of Shares: 20,842, Total Amount (EUR): 1,004,956, Average Price (EUR): 48.22, Lowest Price (EUR): 48.04, Highest Price (EUR): 48.72.

Date: 24-10-2024, Number of Shares: 20,572, Total Amount (EUR): 996,651, Average Price (EUR): 48.45, Lowest Price (EUR): 48.10, Highest Price (EUR): 48.60.

Date: 25-10-2024, Number of Shares: 21,808, Total Amount (EUR): 1,057,514, Average Price (EUR): 48.49, Lowest Price (EUR): 48.24, Highest Price (EUR): 48.72.

Total Summary of Buy-Backs

In total, Ageas has purchased 105,596 shares during this period for an aggregated total amount of EUR 5,126,001. The average price per share stands at EUR 48.54, showcasing disciplined buying strategies that cater to market conditions.

Overall Program Impact

Since the program's commencement on September 16, Ageas has successfully repurchased a total of 640,297 shares amounting to EUR 30,841,693. This effort equates to approximately 0.34% of the entire share capital. Such proactive actions underpin Ageas' strategy to bolster shareholder confidence and signify financial robustness.

Looking Forward

Ageas plans to continue evaluating market conditions and will adjust its purchase strategy as necessary to optimize shareholder value. The ongoing commitment to this buy-back initiative reflects the company's confidence in its business model and future profitability.

Frequently Asked Questions

What is Ageas' share buy-back program?

Ageas' share buy-back program is a strategic initiative aimed at purchasing its shares back from the market to increase shareholder value and optimize capital structure.

How many shares has Ageas bought back recently?

Recently, Ageas bought back 105,596 shares as reported from October 21 to October 25.

What was the average price per share for the recent buy-backs?

The average price per share during the recent buy-backs was EUR 48.54.

Since the program's inception, how many shares has Ageas purchased?

Since the program began on September 16, Ageas has purchased a total of 640,297 shares.

How does the buy-back program affect shareholders?

The buy-back program can benefit shareholders by potentially increasing share prices and providing a more favorable return on investment as the number of outstanding shares decreases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Western Microsurgical Expands Through Strategic Acquisitions

Updated Category News Views 67

Western Microsurgical's Bold Moves Western Microsurgical (WMS) is out here making waves, pulling off some serious strategic plays with the acquisitions of Q Surgical and Proficient Surgical. Now, this ain't some fly-by-night decision—this is about securing territory and leveling up their game in surgical microscopes and operating room supplies. With a footprint that'll...

Continue Reading
U.S.-Saudi Business Leaders Eye Growth Amid Challenges

Updated Category News Views 107

Revitalizing a Strategic Partnership Monday's meeting of the U.S.-Saudi Business Council wasn't just another gathering of suits; it was about re-kindling the investment flame between these two economic giants. Chaired by powerhouses Lubna Olayan and Jane Fraser, this wasn't a mere photo op. It was a call to arms in a landscape riddled with hurdles but bursting with...

Continue Reading
DexCom Faces Scrutiny: Fiduciary Breach Questioned

Updated Category News Views 190

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

Continue Reading
North Fork Mono Casino Opens: A $750 Million Bet

Updated Category News Views 57

A New Spin in Madera Cue the fanfare, folks! The North Fork Mono Casino just threw open its doors earlier than expected today, marking a hefty $750 million wager right in the heart of California's Central Valley. It's a big deal managed by Station Casinos, part of Red Rock Resorts, Inc. (NASDAQ: RRR)—teaming up with the North Fork Rancheria of Mono Indians for a...

Continue Reading
DICK'S Sporting Goods Faces Investor Lawsuit Deadline Looms

Updated Category News Views 23

A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....

Continue Reading
Noma Hits Fortune Cyber 60 with AI Security Success

Updated Category News Views 13

Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...

Continue Reading
oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

Updated Category News Views 57

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

Continue Reading
Bank Leumi Q3 Earnings Preview: Key Dates & Insights

Updated Category News Views 61

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Continue Reading
Jiahui's Bold Leap into Global Cell Therapy Market

Updated Category News Views 66

Jiahui's International Cell Therapy Center: A New Era Jiahui International Hospital is shaking up the healthcare scene with its fresh International Cell Therapy Center, diving headfirst into the cutting-edge world of CAR-T treatments. It's not every day you see this kind of bold move, especially from a player aiming to extend their reach both in China and abroad. Let's...

Continue Reading
CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 19

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading